Molecules involved in developmental signaling pathways have emerged as therapeutic targets for various rheumatic diseases. New research sheds light on the consequences of interfering with these processes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Inflammatory Rheumatic Disorders and Bone
Current Rheumatology Reports Open Access 03 April 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Uderhardt, S. et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. doi: 10.1136/ard.2008.102046.
Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).
van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).
Lories, R. J. U., Derese, I. & Luyten, F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 115, 1571–1579 (2005).
Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).
Park, M. C., Chung, S. J., Park, Y. B. & Lee, S. K. Suppression of bone morphogenetic proteins attenuates syndesmophytosis by down-regulating Smad pathway in aggrecan-induced spondylitis mice [abstract #484]. Arthritis Rheum. 58 (Suppl.), S346 (2008).
Schett, G., Zwerina, J. & David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract. Rheumatol. 4, 473–480 (2008).
Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522–527 (2009).
Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl J. Med. 357, 905–916 (2007).
Luyten, F. P., Lories, R. J., Verschueren, P., De Vlam, K. & Westhovens, R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20, 829–848 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R. J. Lories and F. P. Luyten have acted as patent holders on behalf of Katholieke Universiteit Leuven for the use of noggin in the treatment of spondyloarthritis.
Rights and permissions
About this article
Cite this article
Lories, R., Luyten, F. Wnt antagonists: for better or worse?. Nat Rev Rheumatol 5, 420–421 (2009). https://doi.org/10.1038/nrrheum.2009.144
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.144
This article is cited by
-
Can bone loss in rheumatoid arthritis be prevented?
Osteoporosis International (2013)
-
Inflammatory Rheumatic Disorders and Bone
Current Rheumatology Reports (2012)
-
The balance of tissue repair and remodeling in chronic arthritis
Nature Reviews Rheumatology (2011)